MDM2 inhibition is a promising target in the treatments of AML, serving as a negative regulator of TP53; the activation of TP53 functions induced by any stimuli or DNA damages up-regulates transcription of MDM2 mRNA and codification of protein that in turn links TP53 and directly decreases or inhibits its activity through multiple mechanisms (132). This evidence concerns the gene TP53 and acute myeloid leukemia.